Back to Search
Start Over
Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis.
- Source :
- Future Oncology; May2019, Vol. 15 Issue 13, p1481-1491, 11p
- Publication Year :
- 2019
-
Abstract
- Aim: This pooled safety analysis was conducted to analyze incidence and management of key dacomitinib-associated adverse drug reactions (ADRs). Patients & methods: Patients with EGFR mutation-positive advanced non-small-cell lung cancer who received first-line dacomitinib at the 45 mg/day recommended starting dose were included. ADRs were identified based on reasonable association with EGFR tyrosine kinase inhibitors. Results: Overall, 251/255 patients (98%) experienced ADRs. The most common were diarrhea, rash, stomatitis, nail disorder and dry skin. Dose interruptions and dose reductions were reported in 47 and 52% of patients, respectively. Fewer grade 3 key ADRs were observed following dose reductions. Conclusion: Dacomitinib was generally tolerable. Most reported ADRs were known to be associated with EGFR tyrosine kinase inhibitors and were managed with standard medical management and dose modifications. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14796694
- Volume :
- 15
- Issue :
- 13
- Database :
- Complementary Index
- Journal :
- Future Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 136403021
- Full Text :
- https://doi.org/10.2217/fon-2018-0944